Literature DB >> 2743317

Study of estrogen receptor, progesterone receptor, and the estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and cervix.

D R Ciocca1, L A Puy, L C Fasoli.   

Abstract

The presence of an estrogen-regulated protein with 24,000 molecular weight has been studied in 47 patients with endometrial carcinomas and in 29 patients with cervical carcinomas in order to correlate its presence with that of estrogen receptors (ERs) and progesterone receptors (PgRs). In the cytosol tumor samples the Mr 24,000 protein was detected by the Western blot technique using a monoclonal antibody (C11), while the presence of ER and PgR was studied by the one-point dextran-coated charcoal assay. In the tumor tissue sections immunohistochemistry was applied to detect Mr 24,000 protein, ER, and PgR; in these cases monoclonal antireceptor antibodies (H222 and mPRI) were used to localize the receptor proteins. In endometrial and endocervical adenocarcinomas the presence of Mr 24,000 protein correlated significantly with that of ER (P less than or equal to 0.05) in the cytosol samples; when the evaluation was performed in the tumor sections, the presence of Mr 24,000 protein correlated with that of ER (P less than or equal to 0.005) and PgR (P less than or equal to 0.05) as well. The study also showed that almost 70% of the well-differentiated adenocarcinomas had ER, PgR, and Mr 24,000 protein. In 25% of the endometrial adenocarcinomas examined the tumors were associated with normal, proliferative, and hyperplastic endometrium; in these cases the presence of ER, PgR, and Mr 24,000 protein was evaluated by immunohistochemistry in the malignant and nonmalignant endometrium. On the other hand, there was a lack of correlation between Mr 24,000 protein, ER, and PgR in the squamous carcinomas of the uterine cervix and in the endometrial adenocarcinomas with squamous cells. In most of these cases the tumors lacked ER and PgR although 80% of them contained the Mr 24,000 protein to a variable degree. It is suggested that Mr 24,000 protein is involved in growth and differentiation (the Mr 24,000 protein is a heat shock protein) and that the gene coding of this protein is under hormonal control only in those tissues where growth and differentiation are strongly hormonally controlled (breast and endometrium).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743317

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Immunological evidence for the identity between the hsp27 estrogen-regulated heat shock protein and the p29 estrogen receptor-associated protein in breast and endometrial cancer.

Authors:  D R Ciocca; E H Luque
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

2.  Induction of heat shock protein 27 by hydroxyurea and its relationship to experimental metastasis.

Authors:  A E Eskenazi; J Powers; J Pinkas; S Oesterreich; S A Fuqua; C N Frantz
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

3.  Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue.

Authors:  D R Ciocca; A O Stati; M M Amprino de Castro
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

Review 4.  Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications.

Authors:  Daniel R Ciocca; Stuart K Calderwood
Journal:  Cell Stress Chaperones       Date:  2005       Impact factor: 3.667

5.  Small heat-shock protein is expressed in meningiomas and in granulofilamentous inclusion bodies.

Authors:  N Yokoyama; T Iwaki; J E Goldman; J Tateishi; M Fukui
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Deoxyribonucleic acid damage induced by doxorubicin in peripheral blood mononuclear cells: possible roles for the stress response and the deoxyribonucleic acid repair process.

Authors:  Silvina B Nadin; Laura M Vargas-Roig; F Darío Cuello-Carrión; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

7.  Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study.

Authors:  B Têtu; J Brisson; J Landry; J Huot
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

8.  Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin.

Authors:  Daniel R Ciocca; Viviana R Rozados; F Darío Cuello Carrión; Silvia I Gervasoni; Pablo Matar; O Graciela Scharovsky
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

9.  Induction of Hsp22 (HspB8) by estrogen and the metalloestrogen cadmium in estrogen receptor-positive breast cancer cells.

Authors:  Xiankui Sun; Jean-Marc Fontaine; Ingrid Bartl; Babak Behnam; Michael J Welsh; Rainer Benndorf
Journal:  Cell Stress Chaperones       Date:  2007       Impact factor: 3.667

10.  Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients.

Authors:  D R Ciocca; L A Puy; L C Fasoli; O Tello; J C Aznar; F E Gago; S I Papa; R Sonego
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.